Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Conditions

• Relapsed or Refractory T Cell Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ONO-4685 — DRUG
  ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed

Study Details

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

Key Dates

Start date

Dec 10, 2021

Status verified

Feb 2026

Primary completion

Aug 31, 2027

Completion

Aug 31, 2028

Study Design

Enrollment

217 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: ONO-4685 monotherapy
  Patients with relapsed or refractory T cell Lymphoma who meet eligibility criteria will be enrolled to receive ONO-4685 monotherapy

Primary Outcome Measure

Incidence, nature, and severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs). [ Time Frame: Through study completion, an average of 1 year ]

Central Contacts

• North America Clinical Trial Support Desk
  +18665877745(Toll-Free)
  [email protected]
• International Clinical Trial Support Desk
  +17162141777(Standard)
  [email protected]

Locations (20)

Find similar trials in Birmingham, AL